Avantax Advisory Services’s 10x Genomics TXG Stock Holding History

Avantax Advisory Services’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$156K	Buy	+13,474	New	+$123K	﹤0.01%	2247

Other funds holding TXG

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Avantax Advisory Services's TXG Position: Q2 2025 in Review

Avantax Advisory Services opened a new position in 10x Genomics (TXG) in Q2 2025: 13,474 shares worth $156K. The stake represents ﹤0.01% of the portfolio and ranks #2247 among its holdings.

297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.

Avantax Advisory Services held 13,474 shares of 10x Genomics worth $156K as of Q2 2025.
10x Genomics was a new Avantax Advisory Services position in Q2 2025.
10x Genomics made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2247 holding.
297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.